Program

Thursday, June 14, 2012

8:15 Registration
8:45 President
8:50 Enrico Mihich
9:00 David Livingston
8:45 Jeffrey Engelman

Welcome
Introduction
Focus & Goals
– Keynote Address: Challenges in overcoming resistance to kinase inhibitors

Session I, Genetics of Resistance I
Chair/Moderator: Lewis Chodosh

10:00 Lewis Chodosh
10:25 Discussion
10:45 Elaine Mardis
11:30 Thomas O’Hare
12:15 Discussion
12:35 Levi Garraway
13:00 Discussion
13:20 Lunch

– Mechanisms of tumor dormancy and recurrence
– Genomic exploration of tumor resistance
– Compounding the problem of clinical resistance to TKIs in CML
– Defining the spectrum of resistance to targeted anti-cancer agents

Session II, Clinical Advances in Overcoming Resistance
Chair/Moderator: Jos Baselga

14:30 Jose Baselga
14:55 Discussion
15:15 Jeff Sosman
15:40 Discussion
16:00 Johan deBono
16:25 Discussion
16:45 Adjourn

– Reverting endocrine resistance by targeting the mTOR pathway: A new paradigm in the therapy of breast cancer
– Clinical approaches to BRAF inhibitor resistance in melanoma
– Improving outcome from prostate cancer

Program

Friday, June 15, 2012

Session III, Resistance through Perturbed Signaling
Chair/Moderator: Richard Marais

8:30 Richard Marais
8:55 Discussion
9:15 Alberto Bardelli
9:40 Discussion
10:00 Coffee break
10:20 Neal Rosen
10:45 Discussion
11:05 Rafaela Sordella
11:30 Discussion
11:50 Poster Session & Lunch

– BRAF and RAS signaling in cancer; translating basic understanding into clinical benefit
– Mechanisms of resistance to EGFR targeted therapies in colorectal cancer
– Adaptive resistance to oncogene inhibition
– Intrinsic and extrinsic mechanisms of erlotinib resistance in NSCLC
– Defining the spectrum of resistance to targeted anti-cancer agents

Session IV, Genetics of Resistance II
Chair/Moderator: William Sellers

14:00 William Sellers
14:25 Discussion
14:45 Jos Jonkers
15:10 Discussion
15:30 Roman Thomas
15:55 Discussion
16:25 Giulio Superti-Furga
16:50 Discussion
17:10 Silvia Buonamici
17:35 Discussion
17:50 Adjourn
20:00 Symposium Dinner

– Approaches to the discovery and treatment of therapeutic resistance
– Studying therapy response and resistance in mouse models
– Lung cancer genomics
– Effectors and targets of anti-cancer agents
– Identifying the mechanisms of resistance to smoothened inhibitors

Program

Saturday, June 16, 2012

Session V, Role of the Tumor Microenvironment in Resistance
Chair/Moderator: David Tuveson

9:00 David Tuveson
9:25 Discussion
9:45 Ben Stanger
10:10 Discussion
10:30 James Allison
10:50 Discussion
11:20 Todd Golub
11:45 Discussion
12:05 David Livingston
12:30 Lunch & Adjourn

– The pancreatic tumor stroma influences therapeutic response
– The dynamics of primary tumor spread in pancreatic cancer
– Immune checkpoint blockade: New insights and opportunities
– Systematic approaches to discovering microenvironment-mediated drug resistance
– Concluding Remarks

Program

Invited Participants

- James Allison
  Memorial Sloan Kettering Cancer Ctr, New York, NY
- Alberto Bardelli
  Inst for Cancer Res & Treatment, Candioio, Torino, Italy
- Jose Baselga
  Massachusetts General Hospital, Boston, MA
  Vall D’Hebron Inst of Oncology, Barcelona, Spain
- Silvia Buonamici
  Novartis Inst for Biomedical Res, Cambridge, MA
- Lewis Chodosh
  Univ of Pennsylvania, Philadelphia, PA
- Johann De Bono
  Institute of Cancer Research, London, UK
- Jeffrey Engelman
  Massachusetts General Hospital, Charlestown, MA
- Levi Garraway
  Dana Farber Cancer Inst, Boston, MA
- Todd Golub
  Broad Inst at MIT, Cambridge, MA
- Jos Jonkers
  Netherlands Cancer Inst, Amsterdam, NL
- David Livingston
  Dana Farber Cancer Inst, Boston, MA
- Richard Marais
  The Inst of Cancer Research, London, UK
The Pezcoller Foundation

The Pezcoller Foundation is a non-profit organisation created in 1980 by Prof. Alessio Pezcoller (1896 - 1993), Chief Surgeon of Santa Chiara Hospital of Trento, Italy. The goal of the Foundation is to promote biomedical research.

Activities:
- PEZCOLLER FOUNDATION-AACR INTERNATIONAL AWARD FOR CANCER RESEARCH – 75.000 Euro: this prize is presented, every year, to a scientist who has made a major scientific discovery in the field of cancer.
- PEZCOLLER FOUNDATION-ECCO RECOGNITION FOR CONTRIBUTION TO ONCOLOGY – 30.000 Euro: this prize is presented, every two years to a single individual (scientist, clinician, nurse, etc.) for his/her professional life dedication to the improvement of cancer treatment, care and research.
- THE PEZCOLLER SYMPOSIA: a series of annual symposia promoting interactions among scientists working at the cutting edge of basic oncological sciences.
- PEZCOLLER SEMINARS: a series of educational meetings for medical doctors.
- PEZCOLLER FOUNDATION FELLOWSHIPS: for professional updating in oncology.
- PEZCOLLER FOUNDATION GRANTS: for oncological research programs.
- THE PEZCOLLER FOUNDATION JOURNAL: this periodical is published in order to provide a direct link, at six month interval, between the Pezcoller Foundation and the international medical and scientific community.

This Symposium is supported by
- Fondazione Cassa di Risparmio di Trento e Rovereto
- Provincia Autonoma di Trento
- Comune di Trento
- Comune di Rovereto

24th Pezcoller Symposium

MOLECULAR BASIS FOR RESISTANCE TO TARGETED AGENTS

Trento, Italy, June 14-16, 2012

Co-Chairmen and Program Committee
Richard Marais, William Sellers, David Livingston and Enrico Mihich

The topic will be Molecular Basis for Resistance to Target Agents and the focus of the meeting will be the mechanisms of resistance to new tumour target therapies. The Symposium will be opened by the keynote address of Prof. J. Engelman, MGH. The meeting is being co-organized by William Seller (UK), Richard Marais (UK), David Livingston (Dana Farber Cancer Institute) and with the collaboration of Enrico Mihich (Dana Farber Cancer Institute) There will be 22 speakers divided in five sessions: A) the genetics of this phenotype; B) cooptation of specific signal transduction events resulting in drug resistance; C) advanced approaches to screening for various forms of resistance; D) non-tumor cell directed resistance processes; E) clinical advances in overcoming resistance. Speakers give approximately 25 minute talks followed by a similar amount of time for audience discussion. These meetings have regularly provided a fertile climate for highly revealing and stimulating scientific discussion on topics of extraordinary interest in cancer science.